Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,693 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asthma (Diagnosis) Clear all
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Children With Uncontrolled Asthma

NCT02948959
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

School-based Asthma Therapy: Stage 2 Effectiveness Study

NCT01175369
View directory record Official record
Conditions
Asthma
Interventions
School-based Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 10 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 3, 2026, 1:57 PM EDT
Completed No phase listed Observational

A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma

NCT02163096
View directory record Official record
Conditions
Benign Joint Hypermobility Syndrome, Wheezing, Asthma
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 16 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 3, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

NCT02680561
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations

NCT02066129
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 44 mcg, Fluticasone 220 mcg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 3, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563, Placebo Comp., Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Fall Epidemic Viral Pediatric Study

NCT01192178
View directory record Official record
Conditions
Asthma
Interventions
FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
38
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 3, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

NCT02687815
View directory record Official record
Conditions
Asthma
Interventions
vitamin D3 4000 IU, Placebo
Drug
Lead sponsor
Juan Celedon, MD
Other
Eligibility
6 Years to 16 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Asthma In-Home Monitoring (AIM) Trial

NCT00282516
View directory record Official record
Conditions
Mild, Moderate and Severe Persistent Asthma as Defined by NHLBI-2 Guidelines
Interventions
In-home telemonitoring of pediatric patients with persistent asthma
Procedure
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tripler AMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Positive Airway Pressure for the Treatment of Asthma

NCT01154699
View directory record Official record
Conditions
Asthma, Sleep Apnea
Interventions
Bilevel PAP (4 weeks), Usual Care (4 weeks), Washout Period (4 weeks)
Device · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

NCT03444298
View directory record Official record
Conditions
Airway Inflammation, Asthma
Interventions
Gamma Tocopherol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 3, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

NCT01290887
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Electrophilic Fatty Acid Derivatives in Asthma

NCT01733485
View directory record Official record
Conditions
Asthma, Electrophilic Fatty Acids
Interventions
Aspirin, Indomethacin
Drug
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 3, 2026, 1:57 PM EDT
Terminated No phase listed Observational Results available

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

NCT02487394
View directory record Official record
Conditions
Asthma, COPD
Interventions
Exhaled Breath Condensate (EBC)
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With Asthma

NCT00890175
View directory record Official record
Conditions
Asthma
Interventions
Inhaled loxapine @ 0 & 10 h, Inhaled placebo @ 2 & 10 hours
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

NCT03380429
View directory record Official record
Conditions
Asthma
Interventions
RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

NCT00691873
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Xolair
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Study in Patients With Asthma

NCT00215410
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 12 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Little Rock, Arkansas • Long Beach, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 3, 2026, 1:57 PM EDT
Not listed Early Phase 1 Interventional

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

NCT04250779
View directory record Official record
Conditions
Asthma, Adherence, Medication, Childhood Asthma
Interventions
CapMedic smart inhaler device, Video-based guidance
Device · Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 3, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288
View directory record Official record
Conditions
Asthma
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 3, 2026, 1:57 PM EDT